Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer

Nuclear Medicine Communications

Volumn 30, Issue 9, 2009, Pages 693-699

  Liepe, Knut ^a,d   Geidel, Hans Heiner ^b   Bergmann, Ralf ^c   Haase, Michael ^a   Runge, Roswitha ^a   Kotzerke, Joerg ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Department of Internal Medicine   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^d Hospital Kassel   (Germany)

Author keywords

Animal model; Autoradiography; Osteoblastic bone metastases; Prostate cancer; Rhenium 188 hydroxyethylidine diphosphonate

Indexed keywords

HYDROXYETHYLIDINE DIPHOSPHONATE RHENIUM 188; RADIOISOTOPE; RHENIUM 188; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BONE METASTASIS; CONTROLLED STUDY; MALE; NONHUMAN; RADIATION DOSE; RAT; TRABECULAR BONE; TUMOR CELL;

ANIMALS; AUTORADIOGRAPHY; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ETIDRONIC ACID; LUMBAR VERTEBRAE; MALE; OSTEOBLASTS; PROSTATIC NEOPLASMS; RADIOISOTOPES; RATS; RHENIUM; TISSUE DISTRIBUTION;

EID: 68249154928     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832cc23c     Document Type: Article

References (38)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL,Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95:1276-1299.
3. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88:2989-2994.
4. Pentyala SN, Lee J, Hsieh K, Waltzer WC, Trocchia A, Musacchia L, et al. Prostate cancer: a comprehensive review. Med Oncol 2000; 17:85-105.
5. Dafermou AF, Colamussi PF, Giganti MF, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28:788-798. (Pubitemid 32662540)
6. Enrique O, Zhonyun P, Prma EP, Pusuwan P, Ricobona G, Tian JH, et al. Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med 2002; 1:21-27.
7. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000; 27:123-130.
8. Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF Jr, Franke WG. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 2003; 44:953-960. (Pubitemid 39663408)
9. Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 2003; 89:625-629. (Pubitemid 37076163)
10. Maxon HR 3rd, Schroder LE,Washburn LC, Thomas SR, Samaratunga RC, Biniakiewicz D, et al. Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med 1998; 39:659-663.
11. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in-vivo. Science 1969; 165:1264-1266.
12. Rohlin M. Whole-body autoradiography of 99Tcm-labelled ethylene-1-hydroxy-1, 1-diphosphonate (EHDP) in young rats. Acta Radiol Ther Phys Biol 1976; 15:410-416. (Pubitemid 8001259)
13. Kaplan E, Miree J Jr, Hirsh E, Fields T. Autoradiographic localization of P32 phosphate in metastatic carcinoma of the breast to bone. Int J Appl Radiat Isot 1959; 5:94-98.
14. Russell RG, Fleisch H. Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects. Clin Orthop Relat Res 1975; 108:241-263.
15. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34:689-694. (Pubitemid 23115673)
16. Swailem FM, Krishnamurthy GT, Srivastava SC, Aguirre ML, Ellerson DL, Walsh TK, et al. In-vivo tissue uptake and retention of Sn-117m(4+ )DTPA in a human subject with metastatic bone pain and in normal mice. Nucl Med Biol 1998; 25:279-287.
17. Van Rensburg AJ, Alberts AS, Louw WK. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. J Nucl Med 1998; 39:2110-2115.
18. Dunning WF. Prostate cancer in the rat. Natl Cancer Inst Monogr 1963; 12:351-369.
19. Isaacs JT, Yu GW, Coffey DS. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol 1981; 19:20-23.
20. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986; 9:261-281. (Pubitemid 17215900)
21. Geldof AA, Rao BR, de Voogt HJ. Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Anticancer Res 1986; 6:837-840.
22. Liepe K, Geidel H, Haase M, Hakenberg OW, Runge R, Kotzerke J. New model for the induction of osteoblastic bone metastases in rat. Anticancer Res 2005; 25:1067-1073. (Pubitemid 40546882)
23. Geldof AA, Rao BR. Prostatic tumor (R3327) skeletal metastasis. Prostate 1990; 16:279-290.
24. Haq M, Goltzman D, Tremblay G, Brodt P. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 1992; 52:4613-4619.
25. Nam RK, Jewett MA, Krahn MD. Prostate cancer: 2. Natural history. CMAJ 1998; 159:685-691.
26. Saad F, Schulman C. Role of bisphosphonates in prostate cancer. Eur Urol 2004; 45:26-34.
27. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
28. Geldof AA, van den Tillaar PL, Newling DW, Teule GJ. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model. Urology 1997; 49:795-801.
29. Sontag W. Age-dependent morphometric alterations in the distal femora of male and female rats. Bone 1992; 13:297-310.
30. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40:37S-61S.
31. Blouin S, Basle MF, Chappard D. Rat model of bone metastases. Clin Exp Metastasis 2005; 22:605-614.
32. Ben-Josef E, Lucas DR, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation. Nucl Med Commun 1995; 16:457-463.
33. Ben-Josef E, Maughan RL, Vasan S, Porter AT. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun 1995; 16:452-456.
34. Shah AP, Bolch WE, Rajon DA, Patton PW, Jokisch DW. A paired-image radiation transport model for skeletal dosimetry. J Nucl Med 2005; 46:344-353. (Pubitemid 43073446)
35. Breen SL, Battista JJ. Cavity theory applied to the dosimetry of systemic radiotherapy of bone metastases. Phys Med Biol 2000; 45:879-896.
36. 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007; 28:623-630.
37. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336-341. (Pubitemid 32128538)
38. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21:2869-2875. (Pubitemid 46621835)